How does the WHO decide guidelines on obesity drugs for children?
WHO advises against obesity drugs for children under 10, pointing to healthy eating and exercise instead, and this page shows the evidence and grading behind such guidance.
Covers: This page explains the WHO's guideline development process for paediatric obesity pharmacotherapy, including evidence review, expert panels, conflict-of-interest rules, and how recommendations are graded. It does not give individual medical advice or compare specific drugs for treatment decisions.
Also answers: How does WHO make obesity drug guidelines for kids? · WHO process for childhood obesity medication guidelines? · Who decides WHO obesity drug guidance for children? · WHO guideline development for pediatric obesity drugs?
- One page for this question6 other ways of asking lead here
- 4 independent sourcesEvery claim links to what supports it
- 3 connected pages3 changed this week
- Clean discussionScreened before anything appears
Before you read, make a guess
Fill in the blank: ?% of children on subsidised semaglutide in Iceland achieved reductions over 10 pp
Drag the slider to fill in the blank
The short answer
Interpretation AI-prepared starting mapThe World Health Organization has issued global guidance warning against obesity drugs for children under 10, with care focused instead on healthy eating and exercise rather than medicines such as weight-loss injections. This page is about how WHO arrives at such guidance: the evidence review, expert panels, conflict-of-interest rules and grading of recommendations behind it. The sources available here cover the guidance itself and the kind of evidence that feeds into it — a network meta-analysis of 41 randomised trials (N = 3923) in children and adolescents, and a nationwide Icelandic cohort of children treated with subsidised semaglutide — but they do not describe WHO's internal process step by step.123
- Evidence 12
- Interpretation 6
Did this answer your question?
Be the first to voteIn brief
WHO's new global guidelines warn against obesity drugs for children under 10, directing care towards healthy eating and exercise instead of medicines such as weight-loss injections.1
Evidence-backedThe trial evidence behind this class of drugs is substantial: 41 randomised trials with 3923 children and adolescents, in which semaglutide gave the largest BMI-percentile reduction (MD -20.40%) and phentermine-topiramate the next largest (MD -18.35%) versus lifestyle modification alone.2
Evidence-backedReal-world Icelandic data show semaglutide associated with reversal of an upward weight trajectory in children, with 63% achieving reductions over 10 pp, under a universal subsidy that supported high treatment persistence.3
Evidence-backedGuidelines are graded by strength and direction, and implementation is a separate problem: in one country, 67.2% of WHO health-system recommendations had not been implemented and 54.1% needed a health-system arrangement.4
Evidence-backed
At a glance
The picture in numbers
Live · updated just now
41 trials
3,923 children and adolescents
63%
63 in every 100
67.2%
67 in every 100
The evidence behind it
4 sources- Reviews of many studies1
- Other studies and data2
- Background1
Published in 2026
| Source | Kind | Year |
|---|---|---|
| New global guidelines warn against obesity drugs for children under 10 | Background | 2026 |
| Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. | Reviews of many studies | 2026 |
| Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study. | Other studies and data | 2026 |
| Developing a strategy for identifying recommendations prioritized for implementation in the Colombian health system. | Other studies and data | 2026 |
The community around it
No one has added to this page yet. Firsthand experience, a newer study or a different reading of the numbers would show up here, credited to you.
What it means for you
Which fits you?
Pick the situation closest to yours. Each answer says what it rests on.
If you want to know what WHO currently recommends for children under 10
the guidance warns against obesity drugs and points to healthy eating and exercise as the focus of care.1
Evidence-backedIf you are weighing how strong the trial evidence for these drugs is
a network meta-analysis of 41 RCTs (N = 3923) found semaglutide gave the largest BMI-percentile reduction versus lifestyle modification alone (MD -20.40%), followed by phentermine-topiramate (MD -18.35%), with liraglutide and exenatide also significant but smaller.2
Evidence-backedIf you are interested in how these drugs perform outside trials
an Icelandic nationwide cohort found semaglutide associated with trajectory reversal of -0.86 pp/month, reductions of 5.17 pp at six months and 10.33 pp at 12 months, and 63% of children exceeding a 10 pp reduction, under universal subsidy.3
Evidence-backedIf you assume a published guideline is automatically in use
the Colombian analysis found 67.2% of WHO health-system recommendations had not been implemented there, and 54.1% of all recommendations needed a health-system arrangement — most often around availability of care.4
Evidence-backedIf you want to follow the formal WHO guideline-development steps for paediatric obesity drugs
the sources here do not document panel composition, conflict-of-interest rules, consultation or the grading mechanics, so those steps remain open questions on this page.1
InterpretationThe full story · 3 chapters
01
What WHO has said about obesity drugs for children
AI summary:WHO's global guidelines warn against obesity drugs for children under 10, directing care to healthy eating and exercise instead of medicines.
Evidence-backed: WHO's new global guidelines warn against obesity drugs for children under 10, with care directed at healthy eating and exercise rather than medicines such as weight-loss injections.1
Interpretation: The guidance is framed as a global recommendation, which means it is written for health systems and clinicians across countries rather than as advice for an individual child.1
02
The evidence base that such guidance has to weigh
AI summary:A 41-trial network meta-analysis and an Icelandic cohort show how trial and real-world evidence feed into guideline decisions.
Evidence-backed: A network meta-analysis pooled 41 randomised controlled trials with 3923 participants. Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (mean difference -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years reaching at least 5% and at least 10% BMI reduction respectively. Phentermine-topiramate came next (MD -18.35%, 95% CI -22.26 to -14.45), corresponding to 554 and 734 additional responders per 1000 person-years. Liraglutide and exenatide also significantly reduced the 95th BMI percentile versus lifestyle modification alone, but by less than semaglutide and phentermine-topiramate. The authors used the GRADE approach to rate overall certainty of evidence and concluded that phentermine-topiramate, with its favourable tolerability, may be the optimal adjunct to lifestyle interventions.2
Evidence-backed: A nationwide retrospective cohort in Iceland followed children with obesity treated with subsidised semaglutide. Treatment was associated with reversal of a longstanding upward weight trajectory: -0.86 percentage points per month (95% CI -1.06 to -0.66), with estimated reductions of 5.17 pp (95% CI 3.98 to 6.36) at six months and 10.33 pp (95% CI 7.96 to 12.71) at 12 months. Overall, 63% achieved reductions in %IOTF30 exceeding 10 pp. Non-diabetes status did not significantly modify treatment response among 56 participants at the Pediatric Obesity Center, but that analysis was underpowered (interaction p = 0.83). The authors note that universal subsidisation enabled high treatment persistence and may inform reimbursement policy elsewhere, while generalisability to settings without universal coverage remains uncertain.3
Interpretation: These two studies illustrate the kinds of inputs a guideline panel has to interpret: randomised trial evidence with effect sizes and responder counts, and real-world observational data on persistence, trajectory change and coverage. They differ in design, setting and what they can support, which is exactly the kind of difference a grading system is meant to make explicit.23
03
What happens after a WHO guideline exists
AI summary:A Colombian study shows guideline strength and direction are recorded separately from whether recommendations are actually implemented.
Evidence-backed: A study of WHO health-system guidance in Colombia examined 958 recommendations: 393 (41.0%) had been updated, 425 (44.4%) were outdated and 140 (14.6%) were close to outdated. By strength and direction, 540 were strong (56.4%), 189 weak (19.7%) and 173 suggested or recommended in a specific context (18.1%); 861 (89.9%) were in favour of the intervention and 97 (10.1%) against. Among 363 recommendations from WHO health-system guidelines, 244 (67.2%) had not been implemented in Colombia. Of the 958 recommendations, 518 (54.1%) required a health-system arrangement to be implemented — 259 in governance, 102 in financial and 503 in delivery — with the most common change relating to availability of care, since many recommendations refer to technologies or services that are approved and publicly funded but not widely accessible.4
Interpretation: This shows that a guideline's strength and direction are recorded separately from whether it is actually implemented, and that most of the work of putting a recommendation into effect often falls on health-system arrangements rather than on the recommendation text itself.4
Your turn
Have your say
See where others stand. Join free to add your perspective. One answer per account.
How do you feel about this?
No votes yetQuick questions from connected pages
Before you go
What to remember
Try to recall each hidden figure before you reveal it. Remembering, not rereading, is what makes it stick.
WHO's new global guidelines warn against obesity drugs for children under , directing care towards healthy eating and exercise instead of medicines such as weight-loss injections.
The trial evidence behind this class of drugs is substantial: randomised trials with 3923 children and adolescents, in which semaglutide gave the largest BMI-percentile reduction (MD -20.40%) and phentermine-topiramate the next largest (MD -18.35%) versus lifestyle modification alone.
Real-world Icelandic data show semaglutide associated with reversal of an upward weight trajectory in children, with achieving reductions over 10 pp, under a universal subsidy that supported high treatment persistence.
Your reading
0 of 3 chaptersThis answer keeps changing
When new evidence or a better source comes in, this page is updated (it's on version 2, last changed 1 hour ago). Follow it to be told when that happens.
Up nextHow does the World Health Organization decide global guidelines on obesity drugs for children?Ask this Sylo
Still wondering about something?
Answers come only from this page's reviewed material, with citations, and say plainly when the page doesn't cover it yet.
Behind this page
Who's adding to it, where it comes from, how it changed and what would make it better. Always open to everyone.
Discussion
Sources
Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.
- 1New global guidelines warn against obesity drugs for children under 10BBC NewsPublished Oct 7, 2026Checked Oct 11, 2026
“Care should focus on healthy eating and exercise, not medicines such as weight-loss injections, says the World Health Organization”
- 2Pharmacotherapy for Children and Adolescents With Overweight or Obesity: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.Diabetes, obesity & metabolism (Luo et al.)Published Jun 17, 2026Checked Oct 11, 2026
“A frequentist network meta-analysis was performed using a random-effects model. We used the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach to evaluate the overall certainty of evidence and categorized the interventions.ResultsA total of 41 RCTs (N = 3923) were included. Compared with lifestyle modification alone, semaglutide produced the largest reduction in the 95th BMI percentile (MD -20.40%, 95% CI -24.22 to -16.58), with an additional 500 and 399 patients per 1000 person-years achieving ≥ 5% and ≥ 10% BMI reduction, respectively. Phentermine-topiramate showed the next largest reduction (MD -18.35%, 95% CI -22.26 to -14.45), corresponding to 554 and 734 additional responders per 1000 person-years. Liraglutide and exenatide also significantly reduced the 95th BMI percentile compared with lifestyle modification alone, although the reductions were smaller than those achieved with semaglutide and phentermine-topiramate.ConclusionsBoth semaglutide and phentermine-topiramate were closely linked to weight management, and phentermine-topiramate, with its favourable tolerability, may serve as the optimal adjunct to lifestyle interventions.”
- 3Real-World Use of Subsidised Semaglutide in Icelandic Children With Obesity: A Nationwide Retrospective Cohort Study.Pediatric obesity (Thorsteinsdottir et al.)Published Aug 1, 2026Checked Oct 11, 2026
“Semaglutide was associated with trajectory reversal at -0.86 pp/month (95% CI, -1.06 to -0.66); estimated reductions were 5.17 (95% CI, 3.98, 6.36) and 10.33 (95% CI, 7.96, 12.71) pp at six and 12 months. On-treatment slopes were numerically similar across settings but not interpretable as evidence of equivalent response. ND-status did not significantly modify treatment response among 56 Pediatric Obesity Center participants (interaction p = 0.83; underpowered). Overall, 63% achieved %IOTF30 reductions exceeding 10 pp.ConclusionsSemaglutide was associated with reversal of a longstanding upward weight trajectory in children with obesity. ND-status did not significantly modify treatment response; analysis was underpowered. Universal subsidisation policy enabled high treatment persistence and may inform reimbursement policy in other countries, though generalisability to settings without universal coverage remains uncertain.”
- 4Developing a strategy for identifying recommendations prioritized for implementation in the Colombian health system.Health research policy and systems (Vélez et al.)Published Sep 10, 2026Checked Oct 11, 2026
“A total of 393 (41.0%) were updated, 425 (44.4%) were outdated and 140 (14.6%) were close to outdated. Regarding the strength and direction of the recommendations, 540 were strong (56.4%), 189 were weak (19.7%) and 173 were suggested or recommended in a specific context (18.1%). Most of the recommendations were in favour of the intervention (n = 861, 89.9%), and only 97 were against the intervention (10.1%). Among the 363 recommendations from the WHO HSGs, 244 (67.2%) had not been implemented in Colombia. Of 958 recommendations, 518 (54.1%) needed a health system arrangement for their implementation: 259 in governance, 102 in financial and 503 in delivery.ConclusionsWe identified 518 recommendations that require change in Colombian health system arrangements. The most common change was related to availability of care, given that many of the recommendations refer to technologies/services approved and publicly funded but not widely available or accessible to different population groups. Further research may evaluate whether this strategy helps to define priorities for implementation.”
How it changed
Published 1 time since Oct 11, 2026.
- Version 2Oct 11, 2026Live now
AI-prepared Starting Map from live research.
- First published version.
Help improve it
The brief is open about what's uncertain. These are the specific gaps that new material would fill.
“What WHO has said about obesity drugs for children” rests on one independent source
A second, independent source that confirms or challenges it would make this part more reliable.
“What happens after a WHO guideline exists” rests on one independent source
A second, independent source that confirms or challenges it would make this part more reliable.
Open questions
Who sits on the WHO panel that develops paediatric obesity pharmacotherapy guidance, and how are members selected and screened for conflicts of interest?
No answers yet
Which grading framework does WHO apply to these recommendations, and how does it translate trial and real-world evidence into strong versus conditional recommendations?
No answers yet
What evidence led WHO to draw the line at under 10 years of age rather than another age threshold?
No answers yet
How are WHO recommendations on childhood obesity drugs adopted, funded and monitored in countries with different health-system arrangements?
No answers yet
Around this topic
Sylos connect: narrower topics report up to broader ones, so what's learned in one place shows up where it matters.